OMER gets negative CHMP opinion on narsoplimab application
The CHMP issued a negative opinion following re-examination of the European marketing authorization application for narsoplimab in TA-TMA.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
OMER Gets EMA CHMP Negative Opinion
Omeros Corporation receives a negative opinion from the EMA CHMP on its marketing authorization application for narsoplimab in TA-TMA